LifeWatch AG
LifeWatch AG: Board of Directors of LifeWatch supports the improved offer by BioTelemetry
LifeWatch AG / Key word(s): Offer Board of Directors of LifeWatch supports improved offer by BioTelemetry Zug/Switzerland, May 29 2017 – LifeWatch AG (SIX Swiss Exchange: LIFE), a leading developer and provider of medical solutions and remote diagnostic monitoring services in the digital health market, announces, that the board of directors has concluded unanimously that also the improved public takeover offer by Cardiac Monitoring Holding Company, LLC, a company of the BioTelemetry group, shall be accepted since the improved offer is in the best interest of LifeWatch and its shareholders and that the improved offer price is fair and adequate. Furthermore, the Board of LifeWatch has been informed that in addition to AEVIS, also Himalaya TMT Fund has indicated to accept the increased offer. Further information can be found in the attached report of the Board of Directors of LifeWatch.
About LifeWatch AG About BioTelemetry
BioTelemetry and any of its subsidiaries and any advisor, broker or financial institution acting as an agent or for the account or benefit of BioTelemetry or the Offeror may, subject to applicable Swiss securities laws, rules and regulations, make certain purchases of, or arrangements to purchase, LifeWatch shares from shareholders of LifeWatch who are willing to sell their LifeWatch shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices. The Offeror will disclose promptly any information regarding such purchases of LifeWatch shares in Switzerland through the electronic media and/or the stock exchange and in the U.S. by means of a press release, if and to the extent required under applicable laws, rules and regulations in Switzerland. It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. federal securities laws, since LifeWatch is located in a non-U.S. jurisdiction, and some or all of its officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court’s judgment. The receipt of cash and stock consideration in the Offer by a U.S. shareholder will generally be a taxable transaction for U.S. federal, state and local income tax purposes. Each U.S. shareholder is urged to consult his independent professional adviser immediately regarding the tax consequences of acceptance of the Offer. Securities may not be offered or sold in the U.S. absent registration or an exemption from registration under the U.S. Securities Act. It is expected that the Offer will be subject to a Tier I exemption pursuant to Rule 14d-1(c) of the U.S. Securities Exchange Act of 1934, as amended, and that the issuance of BioTelemetry Common Stock in connection therewith will be exempt from registration under the U.S. Securities Act of 1933, as amended, pursuant to Rule 802 thereof. Neither the Securities and Exchange Commission nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the pre-announcement. Any representation to the contrary is a criminal offense in the U.S. Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=JRLVUEPUXJ Document title: Report of the Board of Directors of LifeWatch End of ad hoc announcement |
Language: | English |
Company: | LifeWatch AG |
Baarerstrasse 139 | |
6300 Zug | |
Switzerland | |
Phone: | +41 41 728 67 78 |
Internet: | www.lifewatch.com |
ISIN: | CH0012815459 |
Valor: | 811189 |
Listed: | Regulated Unofficial Market in Berlin, Stuttgart; Open Market in Frankfurt; SIX Swiss Exchange |
End of Announcement | EQS Group News Service |